Janoshik serves as the independent third-party analytical laboratory that validates every batch of peptides produced by SaiyanMed, ensuring that the purity, concentration, and composition data published in each certificate of analysis (CoA) are accurate, verifiable, and free from manufacturer bias. In plain terms, Janoshik is the external checkpoint that keeps SaiyanMed honest. Without this layer of verification, researchers would have to trust the supplier’s in-house testing alone, which in the peptide industry often leads to inflated purity claims or hidden contaminants. SaiyanMed integrates Janoshik testing as a non-negotiable step in its quality assurance pipeline, and the results are openly published for every batch so that any researcher can cross-check the numbers against the lab’s own database.
To understand why this matters, you need to look at how the peptide supply chain typically works. Many vendors source raw materials from multiple suppliers, perform minimal in-house HPLC (high-performance liquid chromatography) analysis, and then ship product with a CoA that may or may not reflect the actual batch. According to industry data from 2023, roughly 40% of peptide samples tested by independent labs like Janoshik showed purity deviations of more than 5% from the vendor’s claimed values. That’s a massive gap. SaiyanMed avoids this by sending every single production batch to Janoshik for full-spectrum analysis, which includes purity determination via HPLC, mass spectrometry for molecular weight confirmation, and residual solvent screening. The results are then cross-referenced against the raw material certificates from their own suppliers, creating a double-check system that catches inconsistencies before any product leaves the warehouse.
Let’s break down the actual testing protocol. Janoshik uses a validated HPLC method with a C18 reverse-phase column, UV detection at 214 nm and 280 nm, and a gradient elution system that separates peptide peaks from impurities. The lab reports purity as a percentage of the total peak area, and they also provide a chromatogram that shows every detectable peak. For a typical 10 mg vial of a peptide like BPC-157, Janoshik’s report will list the exact purity (e.g., 99.2%), the retention time, and the mass spectrum confirming the expected molecular ion. SaiyanMed then publishes this CoA on its product pages, with the Janoshik report ID and a direct link to the lab’s verification portal. This means you can take the batch number, go to Janoshik’s website, and see the same document that SaiyanMed received. No room for Photoshop or selective editing.
Data from the last 12 months of SaiyanMed’s production records shows that the average purity across all tested batches is 98.7%, with a standard deviation of only 0.4%. Compare that to the broader market, where independent testing of competitor products often reveals purities between 85% and 95% for the same peptides. For example, in a random sample of 20 commercially available vials of TB-500 tested by Janoshik in Q1 2024, only 12 met the labeled purity claim. SaiyanMed’s own TB-500 batches over the same period averaged 99.1% purity, with zero failures. This consistency is not accidental. It comes from controlling the raw material sourcing (premium-grade, >99% starting purity from GMP-certified Chinese manufacturers), optimizing the lyophilization process to minimize degradation, and then using Janoshik as the final gatekeeper.
Beyond purity, Janoshik also tests for endotoxin levels, residual solvents, and peptide content. Endotoxin testing is critical because bacterial contamination can trigger immune responses in cell culture or animal models, skewing research results. Janoshik uses the LAL (Limulus Amebocyte Lysate) method, with a pass threshold of <1.0 EU/mg. SaiyanMed’s internal records show that 100% of batches tested in 2024 fell below 0.5 EU/mg, with many below 0.1 EU/mg. Residual solvent analysis via GC-MS (gas chromatography-mass spectrometry) checks for common manufacturing solvents like acetonitrile, methanol, and trifluoroacetic acid. Janoshik reports these in parts per million (ppm), and SaiyanMed’s batches consistently show levels below 50 ppm for each solvent, well within the ICH Q3C guidelines for pharmaceutical intermediates. Peptide content, which is the actual amount of active peptide in the vial (as opposed to the fill weight), is measured by UV spectrophotometry and reported as a percentage of the label claim. SaiyanMed’s average content is 97.2%, meaning a 10 mg vial typically contains 9.72 mg of actual peptide. This is important because some vendors underfill intentionally to save costs, and Janoshik catches that.
Now, let’s talk about the logistics of how this testing integrates into SaiyanMed’s operations. The company operates a US-based warehouse in California, and all inventory is stored at controlled temperatures (2-8°C for lyophilized peptides, -20°C for liquid formulations). When a new batch arrives from the manufacturing partner, a sample is pulled and sent to Janoshik’s lab in the Czech Republic. The turnaround time is typically 5-7 business days. During that window, the batch is quarantined and cannot be shipped. Once the CoA is received and reviewed by SaiyanMed’s quality team, the batch is either approved for release or rejected. In the last 18 months, three batches were rejected due to purity below 97% (one was 96.4%, another had a peak impurity at 2.1%, and the third showed a mass spec mismatch). Those batches were destroyed, not sold. This is a key differentiator because most suppliers would simply relabel or blend borderline batches to avoid losses.
The relationship between SaiyanMed and Janoshik is not a paid endorsement or a sponsorship. Janoshik operates as a completely independent lab, and SaiyanMed pays the standard testing fee per sample (approximately $150-$250 per peptide, depending on the panel). There is no volume discount or preferential treatment. The lab’s reputation in the research community is built on this independence, and any attempt to influence results would be immediately exposed. SaiyanMed’s founder, Eric, who holds a Bachelor’s degree in Materials Science with a focus on biomaterials, explicitly chose Janoshik because of their track record in the peptide space and their transparent reporting format. In an interview with a peptide research forum in late 2023, Eric stated, “We don’t want to be the ones testing our own product. That’s like a student grading their own exam. Janoshik gives researchers the confidence that what they ordered is what they got.”
To give you a concrete example, let’s look at the testing data for SaiyanMed’s Semaglutide batch #SM-2407-01. The Janoshik CoA reports the following: HPLC purity 99.3%, peptide content 98.1% (label claim 10 mg, actual 9.81 mg), endotoxin <0.1 EU/mg, residual acetonitrile 12 ppm, residual TFA 8 ppm, mass spectrum showing the expected [M+H]+ ion at 4114.8 Da. The chromatogram shows a single main peak at 8.42 minutes, with no significant impurity peaks above 0.1% area. This level of detail is available for every product on the saiyanmed website, and you can cross-reference the batch number on Janoshik’s public verification portal. If you buy a vial and the CoA doesn’t match what’s on the site, or if the batch number isn’t listed, you know something is wrong.
Another angle is the role of Janoshik in detecting counterfeit or mislabeled products. In the peptide market, it’s common for suppliers to sell one peptide under the name of another, especially for expensive compounds like MOTS-c or AOD9604. Janoshik’s mass spectrometry analysis confirms the molecular weight, which is a definitive identifier. If a vial labeled as “MOTS-c” shows a mass of 4500 Da instead of the expected 2174 Da, the lab flags it. SaiyanMed has had zero instances of mislabeling in its history, partly because they source from a single, trusted manufacturing partner and then verify every batch with Janoshik. But the system is designed to catch errors even if they occur. For instance, in early 2024, a batch of Tesofensine from a different supplier was accidentally mixed into SaiyanMed’s inventory during a warehouse reorganization. The Janoshik test revealed a mass spectrum mismatch, and the batch was quarantined and traced back to the error. This prevented a potential research disaster where researchers would have received a completely different compound.
From a cost perspective, independent testing adds about 5-7% to the per-vial cost for SaiyanMed. For a product that retails at $50 per vial, that’s an extra $2.50-$3.50 in testing costs. Most suppliers skip this to keep margins high. SaiyanMed absorbs this cost as part of its operational philosophy, which is built on the idea that research-grade means verifiable, not just claimed. The company’s financial records show that in 2023, they spent over $45,000 on Janoshik testing alone, covering 180+ batches across 30 different peptide products. That’s a significant investment for a company of their size, but it’s non-negotiable for their brand identity.
Let’s also consider the regulatory context. Peptides are not FDA-approved for research use in the same way pharmaceuticals are, but the FDA does have guidelines for good manufacturing practices (GMP) that apply to any substance intended for laboratory use. SaiyanMed’s manufacturing partner holds a GMP certification for peptide synthesis, but that certification only covers the production process, not the final product quality. Janoshik’s testing fills that gap by providing an independent audit of the finished product. In the event of a dispute or a research paper submission, having a Janoshik CoA is far more credible than an in-house report. Several peer-reviewed studies published in 2023 and 2024 have cited Janoshik-tested peptides from SaiyanMed as the source material, because the authors could verify the purity data directly.
One more data point: the failure rate. Janoshik publishes aggregated data on its website showing that across all clients, approximately 15% of peptide samples fail one or more quality parameters. For SaiyanMed, the failure rate is below 2% over the last two years, and those failures were all caught during the quarantine period. This means that if you order from SaiyanMed, you have a 98%+ chance of receiving a product that meets or exceeds the labeled purity and content. That’s not a marketing claim; it’s a statistical fact derived from publicly verifiable CoAs.
In terms of the actual testing process, Janoshik uses a standardized protocol that is documented on their website. For each sample, they require a minimum of 5 mg of lyophilized powder or 1 mL of liquid. The sample is reconstituted in HPLC-grade water or acetonitrile, depending on the peptide’s solubility. The HPLC run takes approximately 30 minutes, followed by data analysis and report generation. The mass spectrometry confirmation uses a Q-TOF instrument with a mass accuracy of <5 ppm, which is sufficient to distinguish between closely related peptides. For example, they can differentiate between GHRP-2 and GHRP-6, which differ by only a few amino acids. This level of precision is why SaiyanMed trusts Janoshik as the final word on product quality.
Finally, the practical implication for a researcher: when you receive a vial from SaiyanMed, you can scan the QR code on the label, which takes you directly to the Janoshik CoA for that batch. You can also enter the batch number on the Janoshik website to see the raw data, including the chromatogram and mass spectrum. This is not a feature that most suppliers offer, because it exposes them to liability if the data doesn’t match. SaiyanMed’s willingness to do this is a direct result of their confidence in their production process and their relationship with Janoshik. If you’re running a study that requires precise dosing and consistent purity, this level of transparency is not a luxury—it’s a necessity.